

EDITORIAL



High-flow nasal cannula in the postoperative period: is positive pressure the phantom of the OPERA trial?

Lorenzo Ball¹ , Lieuwe D. Bos² and Paolo Pelosi^{1*}

© 2016 Springer-Verlag Berlin Heidelberg and ESICM

“Erik is not truly dead. He lives on within the souls of those who choose to listen to the music of the night.”

Gaston Leroux, *The Phantom of the Opera*.

Patients undergoing major abdominal surgery are at risk for the development of postoperative pulmonary complications (PPCs), playing a major role in postoperative morbidity and mortality [1, 2]. Several measures have been proposed to reduce the incidence of PPCs, thus improving the outcome in surgical patients, including protective intraoperative mechanical ventilation [3], chest physiotherapy [4], and postoperative prophylactic or therapeutic non-invasive continuous positive airway pressure (nCPAP) [5] or positive pressure ventilation (NPPV) [6].

High-flow conditioned oxygen therapy, delivered through dedicated high-flow nasal cannulas (HFNCs), has been recently introduced in adults. Randomized controlled trials have tried to clarify the role of HFNCs in the prevention and treatment of respiratory failure in critically ill patients [7] as well as in the postoperative period [8–10]. The exact mode of action of HFNCs is matter of debate, and several mechanisms have been proposed and investigated: positive effects on comfort and tolerance compared to conventional oxygen, stable fraction of inspired oxygen delivery due to a reduction of room air entrainment, dead space wash-out and positive end-expiratory pressure (PEEP) effect [11]. All these aspects could be of value during the postoperative period;

however, few studies investigated the efficacy of HFNCs in this specific setting.

In an article recently published in *Intensive Care Medicine*, Futier and co-authors [12] report a randomized controlled trial (OPERA) in which the clinical value of HFNCs in preventing post-extubation hypoxaemia in non-obese patients undergoing major abdominal surgery was investigated. The primary endpoint was the absolute risk reduction for the occurrence of hypoxaemia at 1 h after extubation, compared to standard oxygen therapy. The authors did not observe any advantage of HFNCs for this endpoint nor concerning the incidence of PPCs. This negative result is in line with previously published small randomized trials that assessed preventive HFNC in the postoperative period in thoracic surgery [8], cardiac surgery [9] and obese cardiac surgery patients [10, 13]. The trial was sized assuming a 50% absolute risk reduction with the use of HFNCs, and incidence of postoperative hypoxaemia of 40%, while the observed incidence was around 20%. This might be in part due to the recent improvements in intraoperative ventilation that reduced the occurrence of postoperative respiratory dysfunction [3]. Sensus stricto, as frequently seen in such studies [14], the huge estimated effect size and high estimated incidence of the primary outcome resulted in an under-powered study. With a pragmatic approach, the authors thoroughly discussed how their cohort of patients was large enough to reject HFNC as a preventive strategy in postoperative patients but not able to detect small differences between the two groups. In fact, in order to achieve statistical significance with the observed incidence, thousands of patients should have been enrolled. Nonetheless, even if a statistically significant difference was found in this setting, its ability to be translated into clinical practice would have been questionable, also because of the

*Correspondence: ppelosi@hotmail.com


¹ IRCCS AOU San Martino-IST, Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Largo Rosanna Benzi 8, 16131 Genoa, Italy

Full author information is available at the end of the article

non-negligible economic burden associated with the routine use of disposable HFNCs. We agree with the authors' interpretation of the trial's results, concluding that the use of postoperative HFNC after major abdominal surgery should not be considered a standard measure to improve clinical outcome.

When HFNCs were tested in the post-extubation period in critically ill patients, results were more encouraging [7, 15]. Interpreting this discrepancy between the findings in postoperative and critically ill patients can be challenging. The application of nCPAP or NPPV is the only known measure able to re-expand

collapsed lung tissue and revert atelectasis, even though only poor degree of evidence is available to support that this translates into an improved outcome [5, 6]. As illustrated in Fig. 1, the evidence arising from trials seems to support the hypothesis that HFNCs are able to provide an intermediate solution between conventional oxygen and positive pressure ventilation, whose clinical usefulness depends on the presence of an underlying reversible lung impairment: in this context, HFNCs represent a well-tolerated bridge solution to avoid more uncomfortable or invasive procedures, while the lung condition is improving. This is not the



case for most surgical patients, as in the postoperative period the patient is in a specific condition not often seen in the intensive care unit: the lungs are essentially healthy, and an important role in respiratory function impairment is played by atelectasis, which is also believed to trigger pro-inflammatory mechanisms leading to the development of other PPCs [2]. This might explain the paradoxical result that HFNCs seem beneficial in critically ill patients, while not after elective surgery. In fact, the positive-pressure effect attributable to HFNCs operating at 60 L/min is estimated around 6 cmH₂O, but drops to 3 cmH₂O when the patient opens the mouth [11]. These values are unlikely to be sufficient to re-expand collapsed areas of the lung. Moreover, one of the advantages of HFNCs, namely the higher achieved fraction of inspired oxygen, might be unwanted in patients whose primary lung dysfunction is atelectasis, for the increased risk of gas resorption. In the postoperative period, probably the increasing use of low tidal volume intraoperative ventilation brought us to a plateau in patient safety, and further improvements are difficult to achieve. Exploring the field of post-extubation respiratory assistance seems an interesting field of research, but an integrated approach combining different interventions might be needed to further improve the safety of our patients [2].

In the era of large randomized trials, there is the need for building evidence combining data from physiological studies, small trials and pilot studies. However, the pathophysiological rationale, the mechanism of action of the intervention, the effect size estimation and the expected incidence of the primary endpoint should be carefully taken into account.

Author details

¹ IRCCS AOU San Martino-IST, Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Largo Rosanna Benzi 8, 16131 Genoa, Italy.

² Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands.

Compliance with ethical standards

Conflicts of interest

The authors have no conflict of interest to disclose.

Received: 4 November 2016 Accepted: 8 November 2016

Published online: 16 November 2016

References

1. Serpa Neto A, Hemmes SNT, Barbas CSV et al (2014) Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic review and meta-analysis. *Lancet Respir Med* 2:1007–1015. doi:10.1016/S2213-2600(14)70228-0
2. Ball L, Battaglini D, Pelosi P (2016) Postoperative respiratory disorders. *Curr Opin Crit Care* 22:379–385. doi:10.1097/MCC.0000000000000312
3. Güldner A, Kiss T, Serpa Neto A et al (2015) Intraoperative protective mechanical ventilation for prevention of postoperative pulmonary complications: a comprehensive review of the role of tidal volume, positive end-expiratory pressure, and lung recruitment maneuvers. *Anesthesiology* 123:692–713. doi:10.1097/ALN.0000000000000754
4. Fagevik Ölsén M, Hahn I, Nordgren S et al (1997) Randomized controlled trial of prophylactic chest physiotherapy in major abdominal surgery. *Br J Surg* 84:1535–1538
5. Ireland CJ, Chapman TM, Mathew SF et al (2014) Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery. *Cochrane Database Syst Rev* 8:CD008930. doi:10.1002/14651858.CD008930.pub2
6. Glossop AJ, Shephard N, Shepherd N et al (2012) Non-invasive ventilation for weaning, avoiding reintubation after extubation and in the postoperative period: a meta-analysis. *Br J Anaesth* 109:305–314. doi:10.1093/bja/aes270
7. Hernández G, Vaquero C, Colinas L et al (2016) Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial. *JAMA* 316:1565–1574. doi:10.1001/jama.2016.14194
8. Ansari BM, Hogan MP, Collier TJ et al (2016) A randomized controlled trial of high-flow nasal oxygen (Optiflow) as part of an enhanced recovery program after lung resection surgery. *Ann Thorac Surg* 101:459–464. doi:10.1016/j.athoracsur.2015.07.025
9. Parke R, McGuinness S, Dixon R, Jull A (2013) Open-label, phase II study of routine high-flow nasal oxygen therapy in cardiac surgical patients. *Br J Anaesth* 111:925–931. doi:10.1093/bja/aet262
10. Corley A, Bull T, Spooner AJ et al (2015) Direct extubation onto high-flow nasal cannulae post-cardiac surgery versus standard treatment in patients with a BMI ≥ 30 : a randomised controlled trial. *Intensive Care Med* 41:887–894. doi:10.1007/s00134-015-3765-6
11. Papazian L, Corley A, Hess D et al (2016) Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. *Intensive Care Med* 42:1336–1349. doi:10.1007/s00134-016-4277-8
12. Futier E, Paugam-Burtz C, Godet T et al (2016) Effect of early postextubation high-flow nasal cannula vs conventional oxygen therapy on hypoxaemia in patients after major abdominal surgery: a French multicentre randomised controlled trial (OPERA). *Intensive Care Med* 42:1888–1898. doi:10.1007/s00134-016-4594-y
13. Futier E, Jaber S (2015) High-flow nasal cannula following extubation: is more oxygen flow useful after surgery? *Intensive Care Med* 41:1310–1313. doi:10.1007/s00134-015-3902-2
14. Abdulatif M, Mukhtar A, Obayah G (2015) Pitfalls in reporting sample size calculation in randomized controlled trials published in leading anaesthesia journals: a systematic review. *Br J Anaesth* 115:699–707. doi:10.1093/bja/aev166
15. Maggiore SM, Idrone FA, Vaschetto R et al (2014) Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med* 190:282–288. doi:10.1164/rccm.201402-0364OC

ORIGINAL



Effect of early postextubation high-flow nasal cannula vs conventional oxygen therapy on hypoxaemia in patients after major abdominal surgery: a French multicentre randomised controlled trial (OPERA)

Emmanuel Futier^{1,2}, Catherine Paugam-Burtz³, Thomas Godet¹, Linda Khoy-Ear³, Sacha Rozencwajg³, Jean-Marc Delay⁴, Daniel Verzilli⁴, Jeremie Dupuis¹, Gerald Chanques^{4,6}, Jean-Etienne Bazin¹, Jean-Michel Constantin^{1,2}, Bruno Pereira⁵, Samir Jaber^{4,6*} and OPERA study investigators

© 2016 Springer-Verlag Berlin Heidelberg and ESICM

Abstract

Purpose: High-flow nasal cannula (HFNC) oxygen therapy is attracting increasing interest in acute medicine as an alternative to standard oxygen therapy; however, its use to prevent hypoxaemia after major abdominal surgery has not been evaluated. Our trial was designed to close this evidence gap.

Methods: A multicentre randomised controlled trial was carried out at three university hospitals in France. Adult patients at moderate to high risk of postoperative pulmonary complications who had undergone major abdominal surgery using lung-protective ventilation were randomly assigned using a computer-generated sequence to receive either HFNC oxygen therapy or standard oxygen therapy (low-flow oxygen delivered via nasal prongs or facemask) directly after extubation. The primary endpoint was absolute risk reduction (ARR) for hypoxaemia at 1 h after extubation and after treatment discontinuation. Secondary outcomes included occurrence of postoperative pulmonary complications within 7 days after surgery, the duration of hospital stay, and in-hospital mortality. The analysis was performed on data from the modified intention-to-treat population. This trial was registered with ClinicalTrials.gov (NCT01887015).

Results: Between 6 November 2013 and 1 March 2015, 220 patients were randomly assigned to receive either HFNC ($n = 108$) or standard oxygen therapy ($n = 112$); all of these patients completed follow-up. The median duration of the allocated treatment was 16 h (interquartile range 14–18 h) with standard oxygen therapy and 15 h (interquartile range 12–18) with HFNC therapy. Twenty-three (21 %) of the 108 patients treated with HFNC 1 h after extubation and

*Correspondence: s-jaber@chu-montpellier.fr

⁴ CHU de Montpellier, Département Anesthésie Réanimation B (DAR B), Hôpital Saint Eloi, 80 Avenue Augustin Fliche, 34295 Montpellier, France
Full author information is available at the end of the article

Take-home message: Among patients at moderate to high risk of postoperative pulmonary complications undergoing major abdominal surgery and mechanically ventilated using a lung-protective strategy, preventive application of high-flow nasal oxygen therapy after extubation as compared with standard oxygen therapy did not decrease the incidence of postoperative hypoxaemia.

29 (27 %) of the 108 patients after treatment discontinuation had postextubation hypoxaemia, compared with 27 (24 %) and 34 (30 %) of the 112 patients treated with standard oxygen (ARR 4, 95 % CI -8 to 15 %; $p = 0.57$; adjusted relative risk [RR] 0.87, 95 % CI 0.53–1.43; $p = 0.58$). Over the 7-day postoperative follow-up period, there was no statistically significant difference between the groups in the proportion of patients who remained free of any pulmonary complication (ARR 7, 95 % CI -6 to 20 %; $p = 0.40$). Other secondary outcomes also did not differ significantly between the two groups.

Conclusions: Among patients undergoing major abdominal surgery, early preventive application of high-flow nasal cannula oxygen therapy after extubation did not result in improved pulmonary outcomes compared with standard oxygen therapy.

Keywords: Postoperative hypoxaemia, Oxygen therapy, Postoperative pulmonary complications, Perioperative medicine, High-risk surgery

Introduction

Postoperative respiratory complications are the second most frequent complications after surgery [1], and a major burden in health care [2, 3]. We and others have previously reported that in patients undergoing abdominal surgery, use of lung-protective ventilation is associated with improved clinical outcomes [4, 5]. There remains, however, a significant number of patients who still develop respiratory complications following extubation, especially hypoxaemia [4, 6], thereby suggesting that there is room for improvement in these patients.

Previous studies reported that hypoxaemia, which is one of the most meaningful factors associated with poor patient outcomes, occurs in 10–50 % of patients after surgery [1, 7], depending on patients and surgical conditions. Oxygen therapy is almost invariably applied after elective extubation using low-flow devices to correct residual impairment in oxygenation, but may not always prevent the postoperative deterioration in respiratory function. After disconnection from mechanical ventilation and positive airway pressure, derecruitment of lung areas, with a resulting loss in functional alveolar units, is not uncommon and recently extubated patients are prone to oxygen desaturation.

High-flow oxygen therapy through a nasal cannula (HFNC) is receiving increasing interest as an alternative to standard oxygen therapy and noninvasive ventilation (NIV) in critically ill patients with hypoxaemic respiratory failure [8, 9] and more recently in a mixed population of mechanically ventilated intensive care unit patients at risk for reintubation after extubation [10]. Previous studies have reported several physiological benefits of HFNC [11, 12], among which are a flow-dependent positive airway pressure and increased end-expiratory lung volume, suggesting a possible alveolar recruitment effect. Although it is reasonable to hypothesise a clinical advantage of early and short-term (less than 24 h) application of HFNC after elective extubation to minimize lung derecruitment and prevent hypoxaemia, and

subsequent postoperative morbidity, its effects have not been evaluated in randomised trials in surgical patients to whom HFNC might be applied if used in preference to standard oxygen therapy for treatment duration consistent with usual care (i.e. less than 24 h).

We therefore performed a randomised clinical trial to evaluate the clinical effectiveness of preventive application of HFNC directly after elective extubation, compared with standard oxygen therapy after major abdominal surgery, to decrease the incidence of hypoxaemia after major abdominal surgery. We hypothesised that immediate use of HFNC after extubation may reduce the incidence of hypoxaemia after discontinuation of invasive lung-protective mechanical ventilation.

Methods

Study design

The OPERA trial was an investigator-initiated, multicentre, randomised clinical trial conducted in three university hospitals in France. A detailed description of the study protocol has previously been published before enrolment of patients had been completed [13]. The study protocol and statistical analysis plan were approved for all centres by a central ethics committee (Comité de Protection des Personnes Sud-Est VI, Clermont-Ferrand, France). All patients provided written informed consent before surgery.

Patients

All adult patients scheduled for planned or unplanned abdominal, or abdominal and thoracic, surgery with an anticipated duration of 2 h or more and a moderate to high risk of postoperative pulmonary complications, defined by an ARISCAT risk score [14] of 26 points or more, were eligible for recruitment. The ARISCAT risk score is a weighted scoring system comprising seven independent clinical variables, which identifies patients with low (a score of less than 26 points), intermediate, or high (a score of 45 points or more) risk for developing

postoperative pulmonary complications. Exclusion criteria included lack of informed consent prior to randomisation, body mass index greater than 35 kg/m², life-threatening condition requiring emergency surgery, obstructive sleep apnoea syndrome, and pregnant patients.

Randomisation and masking

Randomisation was performed (in a 1:1 ratio) with the use of a computer-generated assignment sequence and a centralised telephone system accessible round the clock to receive either HFNC or standard oxygen therapy immediately after tracheal extubation. Randomisation was stratified according to study centre and the planned use or non-use of postoperative epidural analgesia, which is a factor that may influence outcomes [15]. An investigator at each centre was responsible for enrolling patients in the trial and ensuring adherence to the protocol. A trained research coordinator, blinded to the randomised intervention, was responsible for centralisation of data from all sites and recording them onto the electronic database. Although the individual assignments of patients could not be masked to staff members who collected data during surgery and in the post-anaesthesia care unit, treatment allocation was concealed to outcome assessors throughout the study. The coordinating centre remained unaware of the trial group outcomes until the database was locked. The trial statistician analysed the results using an analysis plan that had been finalised before the base was locked and before the blinded data were analysed.

Study intervention

All recruitment centres had expertise in the use of HFNC. Standard oxygen therapy was delivered continuously using nasal prongs or facemask (usual care group). In the HFNC oxygen therapy group (HFNC therapy), oxygen was delivered continuously at a gas flow rate of 50–60 L/min through an MR850 heated humidifier and an RT202 breathing circuit (Optiflow™, Fisher and Paykel Healthcare Ltd, Auckland, New Zealand). In each group, oxygen flow was titrated by the bedside nurse to maintain a peripheral oxygen saturation of 95 % or more. During surgery, a standardised lung-protective ventilation strategy was applied as described in previous reports and in the study protocol [2, 4, 13], and consisted in the combined use of low tidal volume, moderate positive end-expiratory pressure and, whenever possible, recruitment manoeuvres [4]. At the end of surgery, tracheal extubation was performed according to predefined criteria [13]. In both groups, the allocated therapy was delivered continuously until 7.00–8.00 a.m., at postoperative day 1, at which time point study treatment was

stopped. Patients received additional oxygen if peripheral oxygen saturation was lower than 93 % after treatment discontinuation (Online Appendix p.12). Treatment was interrupted in the case of acute respiratory failure requiring immediate intubation or in the case of severe respiratory discomfort with the assigned therapy. Decisions about all other aspects of patient care during the intra- and postoperative periods were made by the attending physician according to the expertise of the staff at each centre and routine clinical practice.

Outcomes


The primary outcome was the proportion of patients who developed hypoxaemia, defined as an arterial oxygen tension to inspiratory oxygen fraction ratio of 300 or less, 1 h after extubation [16]. In addition, this outcome was analysed at the end of allocated treatment. Arterial blood gases were measured on room air in all patients.

Secondary outcomes were assessed daily during the first 7 days after surgery, since respiratory events after surgery are commonly seen during this period, and at hospital discharge; these were (a) postoperative pulmonary complications due to any cause, graded on a scale from 0 (no pulmonary complications) to 4 (the most severe complications) [17]; (b) need for additional oxygen therapy after 8.00 am on day 1 (end of treatment) defined as peripheral oxygen saturation at most 93 % on room air; (c) the development of postoperative hypoxaemia, pneumonia, reintubation and/or use of curative NIV because of postoperative respiratory failure; (d) postoperative gas exchange after discontinuation of the allocated treatment; (e) respiratory comfort (graded with the use of a numerical rating scale, ranging from 0 to 10); (f) unexpected intensive care unit (ICU) admission or readmission; (g) ICU and hospital lengths of stay; and (h) in-hospital mortality.

Statistical analysis

Assuming an incidence of hypoxaemia of 40 % after extubation in patients with characteristics comparable to our inclusion criteria [1, 7, 16], we calculated that enrolment of 220 patients would provide the trial with 90 % power to detect a relative difference of 50 % in the primary outcome between the two groups at a two-sided alpha level of 0.05. During the trial, a total of eight patients were excluded after randomisation; surgery was stopped prematurely (surgical duration less than 2 h) in three of the eight patients because of extensive illness, and five had violation of exclusion criteria. An additional eight patients were thus randomly assigned to a study group to obtain the full sample (Fig. 1).

All analyses were performed before the breaking of the randomisation code on data from the modified



intention-to-treat population, defined as all randomly assigned patients except those who could be excluded without the risk of bias (eight patients who underwent randomisation by mistake and who never received the study treatment) (Fig. 1). An interim analysis was performed after enrolment of the first 110 patients to review data relating to patient safety and quality of trial conduct using the Lan and DeMets method (East software, Cytel Inc., Cambridge, MA, USA). Premature discontinuation of the trial was not recommended on the basis of that analysis, and 220 patients were therefore included.

Continuous variables were compared using the unpaired *t* test or the Mann–Whitney *U* test as appropriate. The Shapiro–Wilk test was used to assess normality, and the Fisher–Snedecor test to assess homoscedasticity. Unadjusted Chi squared was used for primary outcome analysis. Adjusted analysis was performed with the use of a random-effects robust Poisson generalized linear model to take into account adjustment for possible confounding covariates selected according to univariate results in

addition to the stratification variables, and to consider within- and between-centre variability (centre as random effect). Results of primary and secondary outcomes are reported as absolute risk reduction with 95 % confidence intervals, and additionally reported as between-group difference. Results of the regression model are reported as relative risk with 95 % confidence intervals.

Longitudinal analysis using mixed models was used to take into account between- and within-subject variability (patient as random effect). Kaplan–Meier curves were plotted to assess the probability of remaining free of postoperative pulmonary complications after discontinuation of the allocated treatment. The time to complications was analysed using a marginal Cox-proportional hazard model with results reported as hazard ratio with 95 % confidence intervals, and proportional-hazard assumption verified using the Schoenfeld test and plotting residuals.

We conducted one post hoc subgroup analysis, which included patients that received recruitment manoeuvres

as part of the lung-protective ventilation strategy, on the basis of the interaction between randomisation group and recruitment manoeuvres (yes/no) in the regression model.

As less than 5 % of data was missing or unavailable, handling of missing data was not applied. All analyses were performed with the use of Stata version 13.0 (Stata-Corp LP, College Station, TX, USA). A two-sided *P* value of less than 0.05 was considered to indicate statistical significance.

Results

Between 6 November 2013, and 1 March 2015, of the 691 patients assessed for trial eligibility, 220 patients underwent randomisation, with 112 patients assigned to the usual care group and 108 patients assigned to the HFNC group (Fig. 1). All patients were included in the final intention-to-treat analysis.

The two groups of patients had similar baseline characteristics (Table 1). The mean (SD) preoperative ARISCAT risk scores for postoperative pulmonary complications were 40.1 (6.4) in the usual care group and 40.9 (8.7) in the HFNC group ($p = 0.48$). The distribution of the main intraoperative variables is reported in Table 2. Clinical care other than the trial intervention was similar, especially mean levels of tidal volumes and positive end-expiratory pressure applied during surgery. Sixty-seven of the 108 patients (62 %) assigned to HFNC and 69 of the 112 patients (62 %) assigned to usual care received recruitment manoeuvres during lung-protective mechanical, without any statistically significant difference between groups ($p = 0.85$). There were no significant between-group differences regarding use of epidural analgesia, blood loss, blood transfusion and volumes of intravenous fluids. All patients were successfully extubated at the end of surgery, without significant difference ($p = 0.89$) in the duration of intraoperative mechanical ventilation. The median duration of the allocated treatment after extubation was 16 h (interquartile range, 14–18 h) in the usual care group and 15 h (interquartile range 12–18 h) in the HFNC group ($p = 0.03$). Eight patients (7.4 %) allocated to the HFNC group required premature discontinuation for discomfort related to the interface [median (IQR) time to cessation of treatment, 1.8 h (0.8–4.5 h)] compared with no patient in the usual care group ($p = 0.003$).

The primary outcome, postoperative hypoxaemia, was met by 21 % of patients (23/108) treated with HFNC and by 24 % of patients (27/112) treated with standard oxygen 1 h after extubation, and by 29 (27 %) of 108 patients and 34 (30 %) of 112 patients after treatment discontinuation [absolute risk reduction (ARR) 4 %, 95 % CI –8 to 15 %, $p = 0.57$] (Table 3). The results of associated univariate and multivariate analyses are provided in the

Online Appendix (p. 3). Following adjustment for baseline covariates, the observed treatment effect remains non-significant [unadjusted relative risk (RR) 0.88, 95 % CI 0.44–1.52]; adjusted RR 0.87, 95 % CI 0.53–1.43; $p = 0.58$) (Table 3 and Online Appendix p. 3). There were no significant between-group differences for any of the secondary outcomes: need for supplemental oxygen therapy for persistent hypoxaemia after treatment discontinuation, grade level of pulmonary complications, number of patients requiring any form of ventilator assistance for acute respiratory failure during the first 7 days after surgery, and service utilization (days in ICU, days in the hospital) (Table 3; Online Appendix p. 13). During the 7-day postoperative follow-up, there was no statistically significant between-group difference in the proportion of patients who remained free of any pulmonary complication (ARR 7, 95 % CI –6 to 20 %, $p = 0.29$; unadjusted RR 1.19, 95 % CI 0.79–1.78; adjusted RR 1.19, 95 % CI 0.80–1.79, $p = 0.40$) (Table 3; Fig. 2).

In a post hoc analysis, there was a significant interaction between use of recruitment manoeuvres during lung-protective ventilation and the treatment group with respect to hypoxaemia after treatment discontinuation ($p = 0.019$). In the subgroup of patients whose lung-protective strategy included recruitment manoeuvres (Online Appendix pp. 6–9), the observed treatment effect was strengthened in the HFNC group as compared with the usual care group (ARR 13, 95 % CI –2 to 27 %, $p = 0.09$; unadjusted RR 0.58, 95 % CI 0.28–1.17; adjusted RR 0.53, 95 % CI 0.26–1.09, $p = 0.08$). There were no significant between-group differences in any of the other outcomes (Online Appendix).

There were no significant between-group differences for patient respiratory comfort, haemodynamics and postoperative gas exchange, 1 h after enrolment and after treatment discontinuation (Online Appendix p. 10).

Discussion

In this multicentre randomised clinical trial, a strategy of preventive application of high-flow nasal oxygen therapy directly after extubation compared with standard oxygen therapy was ineffective at reducing the incidence of hypoxaemia after abdominal surgery. There were also no significant differences in postoperative outcomes, especially pulmonary complications and length of hospital stay.

When planning the study, we assumed an incidence of hypoxaemia of 40 % based on data from previous large cohorts of abdominal surgical patients [1, 7]. Our results showed a lower rate than expected with standard oxygen therapy (30 %), which might have been attributable to overall improvements in perioperative surgical care, to inclusion of patients at lower risk of developing

Table 1 Characteristics of the patients at baseline

Characteristic	No. (%)	
	Usual care (n = 112)	HFNC oxygen therapy (n = 108)
Age (years)	61 (13)	62 (12)
Male sex	64 (57)	61 (56)
Height (cm)	168 (9)	168 (8)
Weight (kg)	70 (14)	70 (13)
Body mass index (kg/m ²)	25 (4)	25 (4)
Predicted body weight (kg) ^a	61 (11)	61 (10)
ASA grade		
1	20 (18)	20 (18)
2	75 (67)	72 (67)
3 or higher	17 (15)	7 (15)
Preoperative risk score ^b		
Moderate risk	95 (85)	90 (83)
High -risk	17 (15)	18 (17)
Comorbidity		
Hypertension	35 (31)	34 (31)
Current smoker	30 (27)	36 (33)
Recent weight loss >10 %	16 (14)	14 (13)
Alcohol intake	8 (7)	14 (13)
COPD	6 (5)	2 (2)
Asthma	2 (2)	8 (7)
Diabetes	13 (12)	12 (11)
Cancer diagnosis	88 (79)	91 (84)
Type of surgery		
Liver resection	46 (41)	38 (35)
Pancreatico-duodenectomy	35 (31)	34 (32)
Gastrectomy	4 (3)	9 (8)
Oesophagectomy	5 (4)	7 (6)
Colorectal resection	13 (12)	14 (13)
Splenectomy	2 (2)	2 (2)
Other	7 (6)	4 (4)
Planned surgery	112 (100)	106 (98)
Laparoscopic surgery	10 (9)	10 (9)
Surgical incision		
Midline	53 (47)	50 (46)
Transverse	47 (42)	46 (43)
Other	12 (11)	12 (11)
Duration of the surgical procedure (min) ^c	300 (190–380)	270 (195–370)

Data are n (%), mean (SD), or median (IQR), unless otherwise stated

ASA American Society of Anaesthesiology physical status classification, COPD chronic obstructive pulmonary disease

^a The predicted body weight was calculated as follows: for men, $50 + 0.91 \times (\text{height in centimetres} - 152.4)$; and for women, $45.5 + 0.91 \times (\text{height in centimetres} - 152.4)$

^b Preoperative risk (ARISCAT) score for postoperative pulmonary complications. The risk index is a scoring system based on seven independent preoperative risk factors indicating three levels of risk: low risk (<26 points), moderate risk (26–44 points) and high risk (≥ 45 points). Patients having moderate or high risks were eligible for inclusion

^c The duration of surgery was calculated as the time between skin incision and closure of the incision

hypoxaemia and, in contrast to previous studies, to the use of lung-protective mechanical ventilation. Our findings for postoperative pulmonary complications are

also consistent with recent data of a large multicentre study in which patients had entry criteria similar to those in our trial [6]. Furthermore, although the overall

Table 2 Clinical management of patients during the surgical period

Variable	Usual care (n = 112)	HFNC oxygen therapy (n = 108)
Duration of mechanical ventilation (min)	390 (290–500)	377 (290–490)
Tidal volume (mL/kg of PBW) ^a		
Start of surgery	7.6 (1.3)	7.4 (1.2)
End of surgery	7.5 (1.3)	7.3 (0.9)
PEEP (cm H ₂ O)		
Start of surgery	6.1 (1.3)	6.3 (1.8)
End of surgery	6.2 (1.3)	6.3 (1.3)
Use of recruitment manoeuvres	69 (62)	67 (62)
Number of recruitment manoeuvres ^b	6 (3)	6 (4)
Plateau pressure (cm H ₂ O)		
Start of surgery	16.4 (3.6)	15.9 (3.0)
End of surgery	16.2 (2.8)	15.6 (3.6)
FiO ₂ (%)	49 (14)	52 (16)
Volume of fluid administered (mL)		
Crystalloids	3000 (2000–4000)	2500 (2000–3500)
Colloids	1000 (500–1500)	750 (500–1000)
Use of epidural analgesia	37 (33 %)	37 (34 %)
Blood loss (mL)	350 (200–700)	350 (150–600)
Blood transfusion	13 (12 %)	12 (11 %)
Use of nasogastric tube	76 (68 %)	63 (58 %)

Data are n (%), mean (SD), or median (IQR) unless otherwise stated

FiO₂ inspired oxygen fraction, PBW predicted body weight, PEEP positive end-expiratory positive pressure

^a The predicted body weight was calculated as follows: for men, $50 + 0.91 \times (\text{height in centimetres} - 152.4)$; and for women, $45.5 + 0.91 \times (\text{height in centimetres} - 152.4)$

^b Recruitment manoeuvres consisted of applying a continuous positive airway pressure of 30 cm H₂O for 30 s

rate of hypoxaemia in the usual care group was lower than anticipated, it is unlikely that patients in the HFNC group would have a relative reduction of 50 % in risk, which limits the value of the present work. Nevertheless, although we are aware that a definitive conclusion cannot be drawn from our findings, an absolute risk reduction of 4 % between the two treatments makes the likelihood of a statistically significant difference difficult to achieve and of limited clinical relevance. These concerns need careful consideration.

To the best of our knowledge, this trial is the first to evaluate the usefulness of preventive application of HFNC directly after extubation in abdominal surgical patients. Despite extensive physiological data [12], there are few data on the use of HFNC in preventing the worsening of respiratory function following surgery. Our findings are consistent with those of two previous randomised trials in cardiac surgical patients in which direct extubation onto HFNC after surgery did not confer clinical advantage in terms of oxygenation and respiratory function over standard oxygen therapy [18, 19].

One notable feature of our trial compared with the existing data was the use of intraoperative lung-protective ventilation. However, lung derecruitment is not

uncommon after extubation and recently extubated patients are prone to oxygen desaturation [20]. Considering the suspected induced effects of HFNC on lung volumes [12], we hypothesised that early initiation of HFNC could minimize in part lung derecruitment after extubation. Unlike recent findings in mechanically ventilated patients at risk for reintubation [9, 10, 21], we failed to detect any major differences in unadjusted or adjusted outcomes between treatment groups. Several hypotheses could explain these results.

First, previous studies have shown a significant variability of the airway pressures during the respiratory cycle with HFNC [22], and that high flow-rate translates into clinically significant airway pressures only with the mouth closed [23]. In keeping with the pragmatic nature of our trial, no attempt was made to ensure that patients had a closed mouth. Although flow rates used in this study are consistent with clinical practice, higher gas flow rates might be required in this setting to minimize lung derecruitment after extubation [24].

Second, previous studies stressed that both the timing after extubation and the duration of treatment are important in determining the clinical effectiveness of noninvasive respiratory support [16]. Although HFNC

Table 3 Results for the primary and secondary outcomes

Outcomes	No./total no. (%)		ARR or between-group difference (95 % CI)	p value
	Usual care	HFNC oxygen therapy		
Primary outcomes				
Postoperative hypoxaemia ^{a,b}				
1 h after extubation	27/112 (24)	23/108 (21)	-3 (-14 to 8)	0.62
After discontinuation of the study treatment	34/112 (30)	29/108 (27)	-4 (-15 to 8)	0.57
Secondary outcomes				
Need for supplemental oxygen therapy after treatment discontinuation	92/112 (82)	79/108 (73)	-9 (-20 to 2)	0.11
Pulmonary complications ^c within 7 days				
Grade 1 or 2	49/112 (44)	37/108 (34)	-10 (-25 to 4)	0.17
Grade ≥3	19/112 (17)	21/108 (20)	2 (-8 to 13)	0.63
Bronchial congestion	14/112 (13)	16/108 (15)	2 (-7 to 11)	0.62
Hypoxaemia ^d	30/112 (27)	30/108 (28)	0 (-11 to 13)	0.87
Pneumonia	10/112 (9)	10/108 (9)	0 (-7 to 8)	0.93
Need for intubation or NIV for respiratory failure ^e	14/112 (13)	20/108 (19)	6 (-4 to 16)	0.22
Surgical reoperation within 7 days ^f	5/112 (4)	2/108 (2)	-3 (-7 to 2)	0.45
Unexpected ICU admission	16/112 (14)	16/108 (15)	0 (-9 to 10)	0.91
ICU length of stay (days)	5 (3-13)	6 (4-16)	3 (-5 to 12)	0.53
Hospital length of stay (days)	11 (7-18)	12 (7-20)	0.5 (-3.5 to 4.5)	0.58
In-hospital mortality	3/112 (3)	2/108 (2)	-1 (-5 to 3)	0.68

Data are *n* (%) or median (IQR) unless otherwise stated

ARR absolute risk reduction, NIV noninvasive ventilation, ICU intensive care unit, BMI body mass index, HFNC high-flow nasal cannula, OSA obstructive sleep apnoea syndrome, HFNC high-flow nasal cannula, PPC postoperative pulmonary complications

^a The primary outcome was the proportion of patients with postoperative hypoxaemia ($\text{PaO}_2/\text{FiO}_2$ of 300 or less), as established previously

^b Relative risk for requiring prophylactic NIV after extubation: unadjusted RR 0.88 (95 % CI 0.54–1.44); adjusted RR 0.87 (95 % CI 0.53–1.43); $p = 0.58$. Adjustment was performed for stratification variables (use or non-use of epidural analgesia and study centre) and preoperative risk of postoperative pulmonary complications (ARISCAT score)

^c Postoperative pulmonary complications were scored with the use of a graded scale ranging from 0 to 4, with grade 0 representing the absence of any pulmonary complications and grades 1–4 representing successively the worst forms of complications

^d Criteria for postoperative hypoxaemia was defined as peripheral oxygen saturation $<92\%$ while breathing at least 10 L/min oxygen, $\text{PaO}_2 <60$ mmHg on room air or $\text{PaO}_2 <80$ mmHg while breathing any supplemental oxygen


^e Acute hypoxaemic respiratory failure was defined by one of the hypoxaemic criteria (peripheral oxygen saturation (SpO_2) $<92\%$ while breathing at least 10 L/min oxygen, $\text{PaO}_2 <60$ mmHg on air or $\text{PaO}_2 <80$ mmHg while breathing any supplemental oxygen) and at least one of the following: severe respiratory distress with dyspnoea, accessory muscle recruitment and paradoxical abdominal or thoracic motion, respiratory rate >25 breaths/min, respiratory acidosis with pH <7.30 and arterial carbon dioxide partial pressure (PaCO_2) >50 mmHg

^f Patients who underwent reoperation were systematically intubated. Only patients who required postoperative mechanical ventilation for at least 6 h were considered a reintubation

was applied directly after extubation, the time needed to produce significant effects may be longer than we anticipated. In keeping with the pragmatic nature of the trial, we aimed to reproduce standard practices in oxygen therapy following elective extubation in surgical patients. Hernandez et al. [10] recently showed that in a low-risk population for reintubation of mechanically ventilated patients for more than 12 h, including 15 % of scheduled surgical patients, 24 h of HFNC therapy after extubation was enough to reduce the reintubation rate. In the present study, HFNC therapy was applied for a median (IQR) duration of 15 (12–18) h, which is consistent with

the routine postoperative monitoring time in the perioperative environment.

Third, there is evolving evidence that during abdominal surgery, low tidal volume ventilation should include recruitment manoeuvres, in addition to moderate levels of PEEP [4, 25]. Previous studies have emphasized the role of low tidal volume ventilation, even when PEEP is applied, on alveolar derecruitment. Low PEEP levels, in the absence of recruitment manoeuvres, may therefore be insufficient to stabilize alveoli and keep them open. Owing to the perceived effects of HFNC on airway pressure and lung volumes, we had assumed that early



HFNC therapy could, at least in part, minimize alveolar derecruitment following extubation if the treatment is initiated on previously recruited lungs. The observed treatment effect was strengthened in the post hoc analysis in the subgroup of patients that received recruitment manoeuvres (18 % in the HFNC group vs 30 % usual care group), which was justified by a significant interaction with study treatment [26]. Hence, the study may have identified a clinical benefit of HFNC for the primary endpoint that did not demonstrate statistical significance because of a possible lack of power.

The findings of previous trials and meta-analyses have suggested the efficacy of moderate levels of continuous positive airway pressure (CPAP) (7–10 cm H₂O) or noninvasive positive pressure ventilation (NPPV) as preventative treatments, applied either continuously or intermittently for a few hours (6–12 h) in high-risk patients following abdominal surgery, by reducing the incidence postoperative pulmonary complications [27]. There is, however, only limited translation to routine clinical practice in the immediate postoperative period because this usually requires experienced staff and admission to a specialized environment. Although the study patient population and treatment duration were close to those of previous studies using CPAP, the findings of the present study may be seen as somewhat predictable. However, the current evidence base for postoperative CPAP has a number of limitations and the effects on hypoxaemia, invasive mechanical ventilation and mortality are uncertain [28].

This study has several limitations. The definition of our primary endpoint was arbitrary and may not adequately reflect disease severity. We are aware that hypoxaemia

might not be considered to be as relevant as patient-centred outcomes, such as reintubation, to guide clinical practice. However, hypoxaemia still remains a matter of concern in daily practice and may be associated with poor patient outcomes. Additionally, our definition is supported in the literature [14, 16] and is not subject to observer bias, and is also highly relevant to clinicians in this surgical population, especially to identify patients who may benefit from an intensification of treatment and initiation of NIV [29]. The current study was intended to explore the effect of HFNC in addition to lung-protective ventilation. Whilst previous studies have shown encouraging results in the abdominal surgery population, its application to routine clinical practice remains uncertain. Whether the use of HFNC may translate into clinical benefits outside this setting deserves further explorations. The study protocol did not include standardisation for different aspects of patient care. It was recommended, however, that the study centres follow routine clinical practice to minimize interference with the trial intervention. Adherence to the use of recruitment manoeuvres during surgery was low (only 61 % of the study population), perhaps resulting in a failure to achieve statistical significance for the primary outcome. Finally, because we studied a homogeneous population of surgical patients, with an overall moderate risk of pulmonary complications, our findings do not preclude the possibility of significant beneficial effects from using HFNC in higher-risk patients.

In conclusion, our study indicates that among patients undergoing major abdominal surgery and receiving intra-operative lung-protective ventilation, preventive application of HFNC after extubation, compared with standard oxygen therapy, did not result in a statistically significant reduction in the incidence of postoperative hypoxaemia. The routine use of postoperative HFNC after extubation does not seem to be justified in similar patients.

Electronic supplementary material

The online version of this article (doi:10.1007/s00134-016-4594-y) contains supplementary material, which is available to authorized users.

Author details

¹ CHU de Clermont-Ferrand, Pôle Médecine Périopératoire (MPO), Hôpital Estaing, 63003 Clermont-Ferrand, France. ² Laboratoire Universitaire, Université d'Auvergne, R2D2-EA 7281, 63000 Clermont-Ferrand, France. ³ AP-HP, Département Anesthésie-Réanimation, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, 75018 Paris, France. ⁴ CHU de Montpellier, Département Anesthésie Réanimation B (DAR B), Hôpital Saint Eloi, 80 Avenue Augustin Fliche, 34295 Montpellier, France. ⁵ CHU de Clermont-Ferrand, Direction de la Recherche Clinique (DRC), 63000 Clermont-Ferrand, France. ⁶ University of Montpellier, INSERM U-1046, CNRS UMR 9214, 34295 Montpellier, France.

Acknowledgments

The OPERA trial investigators would like to thank all patients who participated in the study, and the clinical and research coordinators at all participating sites, especially Dominique Morand (Direction de la Recherche Clinique, DRC, Clermont-Ferrand, France), Albert Prades (Montpellier University Hospital,

Montpellier, France) as well as the nurses and medical staff at all of the participating sites, without whom the OPERA study would never have been completed.

Compliance with ethical standards

Conflicts of interest

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. EF reports receiving consulting fees from Fresenius kabi, and lecture fees from General Electric Healthcare and Fresenius kabi, nonfinancial support from Dräger, and reimbursement of travel expenses from Fisher and Paykel Healthcare. CPB reports receiving consulting fees from Merck Sharp & Dohme, Baxter Gambro and Astellas. TG reports receiving a research grant from LFB Bio-medicaments and meeting support (reimbursement of travel costs) from Baxter Gambro. SJ reports receiving consulting fees from Dräger, Maquet, Hamilton and Fisher and Paykel Healthcare, lecture fees from Abbott and Philips, and reimbursement of travel expenses from Pfizer. The other authors declare no competing interests.

Received: 22 September 2016 Accepted: 12 October 2016

Published online: 22 October 2016

References

- Arozullah AM, Daley J, Henderson WG, Khuri SF (2000) Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. *Ann Surg* 232:242–253
- Serpa Neto A, Hemmes SN, Barbas CS, Beiderlinden M, Fernandez-Bustamante A, Futier E, Hollmann MW, Jaber S, Kozian A, Licker M, Lin WQ, Moine P, Scavonetto F, Schilling T, Selmo G, Severgnini P, Sprung J, Treschan T, Unzueta C, Weingarten TN, Wolthuis EK, Wrigge H, Gama de Abreu M, Pelosi P, Schultz MJ, Investigators PN (2014) Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic review and meta-analysis. *Lancet Respir Med* 2:1007–1015
- Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ (2005) Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. *Ann Surg* 242:326–341
- Futier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A, Marret E, Beaussier M, Gutton C, Lefrant JY, Allaouchiche B, Verzilli D, Leone M, De Jong A, Bazin JE, Pereira B, Jaber S (2013) A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med* 369:428–437
- Serpa Neto A, Hemmes SN, Barbas CS, Beiderlinden M, Biehl M, Binnekade JM, Canet J, Fernandez-Bustamante A, Futier E, Gajic O, Hedenstierna G, Hollmann MW, Jaber S, Kozian A, Licker M, Lin WQ, Maslow AD, Memtsoudis SG, Reis Miranda D, Moine P, Ng T, Paparella D, Putensen C, Ranieri M, Scavonetto F, Schilling T, Schmid W, Selmo G, Severgnini P, Sprung J, Sundar S, Talmor D, Treschan T, Unzueta C, Weingarten TN, Wolthuis EK, Wrigge H, Gama de Abreu M, Pelosi P, Schultz MJ, PROVE Network Investigators (2015) Protective versus conventional ventilation for surgery: a systematic review and individual patient data meta-analysis. *Anesthesiology* 123:66–78
- Hemmes SN, Gama de Abreu M, Pelosi P, Schultz MJ (2014) High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial. *Lancet* 384:495–503
- Lawrence VA, Dhanda R, Hilsenbeck SG, Page CP (1996) Risk of pulmonary complications after elective abdominal surgery. *Chest* 110:744–750
- Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herblant A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Beduneau G, Deletage-Metreau C, Richard JC, Brochard L, Robert R, FLORALI Study Group, REVA Network (2015) High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med* 372:2185–2196
- Stephan F, Barrucand B, Petit P, Rezaiguia-Delclaux S, Medard A, Delannoy B, Cosserant B, Flcoteaux G, Imbert A, Pilorge C, Berard L, BiPOP Study Group (2015) High-flow nasal oxygen vs noninvasive positive airway pressure in hypoxemic patients after cardiothoracic surgery: a randomized clinical trial. *JAMA* 313:2331–2339
- Hernandez G, Vaquero C, Gonzalez P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuenca R, Fernandez R (2016) Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients: a randomized clinical trial. *JAMA* 315:1354–1361
- Papazian L, Corley A, Hess D, Fraser JF, Frat JP, Guitton C, Jaber S, Maggiore SM, Nava S, Rello J, Ricard JD, Stephan F, Trisolini R, Azoulay E (2016) Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. *Intensive Care Med* 11:1–4
- Spoletini G, Alotaibi M, Blasi F, Hill NS (2015) Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. *Chest* 148:253–261
- Futier E, Paugam-Burtz C, Constantin JM, Pereira B, Jaber S (2013) The OPERA trial-comparison of early nasal high flow oxygen therapy with standard care for prevention of postoperative hypoxemia after abdominal surgery: study protocol for a multicenter randomized controlled trial. *Trials* 14:341
- Canet J, Gallart L, Gomar C, Paluzie G, Valles J, Castillo J, Sabate S, Mazo V, Briones Z, Sanchis J (2010) Prediction of postoperative pulmonary complications in a population-based surgical cohort. *Anesthesiology* 113:1338–1350
- Popping DM, Elia N, Marret E, Remy C, Tramer MR (2008) Protective effects of epidural analgesia on pulmonary complications after abdominal and thoracic surgery: a meta-analysis. *Arch Surg* 143:990–999 (discussion 1000)
- Squadron V, Coia M, Cerutti E, Schellino MM, Biolino P, Occella P, Belloni G, Vilianis G, Fiore G, Cavallo F, Ranieri VM (2005) Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. *JAMA* 293:589–595
- Hulzebos EH, Helder PJ, Favie NJ, De Bie RA, Brutel de la Riviere A, Van Meeteren NL (2006) Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. *JAMA* 296:1851–1857
- Corley A, Bull T, Spooner AJ, Barnett AG, Fraser JF (2015) Direct extubation onto high-flow nasal cannulae post-cardiac surgery versus standard treatment in patients with a BMI ≥ 30 : a randomised controlled trial. *Intensive Care Med* 41:887–894
- Parke R, McGuinness S, Dixon R, Jull A (2013) Open-label, phase II study of routine high-flow nasal oxygen therapy in cardiac surgical patients. *Br J Anaesth* 111:925–931
- Futier E, Marret E, Jaber S (2014) Perioperative positive pressure ventilation: an integrated approach to improve pulmonary care. *Anesthesiology* 121:400–408
- Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M (2014) Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med* 190:282–288
- Parke RL, McGuinness SP (2013) Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle. *Respir Care* 58:1621–1624
- Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, Galia F, Futier E, Constantin JM, Jaber S (2013) Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. *Minerva Anestesiol* 79:1344–1355
- Parke RL, Bloch A, McGuinness SP (2015) Effect of very-high-flow nasal therapy on airway pressure and end-expiratory lung impedance in healthy volunteers. *Respir Care* 60:1397–1403
- Yang D, Grant MC, Stone A, Wu CL, Wick EC (2016) A meta-analysis of intraoperative ventilation strategies to prevent pulmonary complications: is low tidal volume alone sufficient to protect healthy lungs? *Ann Surg* 263:881–887
- Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in medicine—reporting of subgroup analyses in clinical trials. *N Engl J Med* 357:2189–2194
- Cabrini L, Landoni G, Oriani A, Plumari VP, Nobile L, Greco M, Pasin L, Beretta L, Zangrillo A (2015) Noninvasive ventilation and survival in acute

care settings: a comprehensive systematic review and metaanalysis of randomized controlled trials. *Crit Care Med* 43:880–888

28. Ireland CJ, Chapman TM, Mathew SF, Herbison GP, Zacharias M (2014) Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery. *Cochrane Database Syst Rev* 8:CD008930
29. Jaber S, Lescot T, Futier E, Paugam-Burtz C, Seguin P, Ferrandiere M, Lasocki S, Mimoz O, Hengy B, Sannini A, Pottecher J, Abback PS, Riu B, Belafia F, Constantin JM, Masseret E, Beaussier M, Verzilli D, De Jong A, Chanques G, Brochard L, Molinari N, NIVAS Study Group (2016) Effect of noninvasive ventilation on tracheal reintubation among patients with hypoxemic respiratory failure following abdominal surgery: a randomized clinical trial. *JAMA* 315:1345–1353



Emmanuel Futier
Samir Jaber

High-flow nasal cannula following extubation: is more oxygen flow useful after surgery?

Received: 19 April 2015

Accepted: 28 May 2015

Published online: 13 June 2015

© Springer-Verlag Berlin Heidelberg and ESICM 2015

This editorial refers to the article available at:
doi:[10.1007/s00134-015-3765-6](https://doi.org/10.1007/s00134-015-3765-6).

E. Futier

Department of Anesthesiology and Critical Care Medicine, Estaing Hospital, University Teaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France

E. Futier

Retinoids, Reproduction and Developmental Disease (R2D2) Unit (EA 7281), University of Clermont-Ferrand 1, 63000 Clermont-Ferrand, France

S. Jaber

Department of Anesthesiology and Critical Care Medicine B (DAR B), Saint Eloi Hospital, University Teaching Hospital of Montpellier, Montpellier, France

S. Jaber

Institut National de la Santé et de la Recherche Médicale (INSERM U-1046), 34295 Montpellier, France

E. Futier (✉)

Pôle Médecine Périopératoire (MPO), Hôpital Estaing, CHU Clermont-Ferrand, 1 place Lucie Aubrac, 63003 Clermont-Ferrand cedex 1, France
e-mail: efutier@chu-clermontferrand.fr
Tel.: +33473750476


Oxygen is one of the most widely available and prescribed therapies in medicine, especially in the perioperative field. General anesthesia for both elective and emergency surgery approximates 15–20 million per

year in the European countries, and most, if not all, patients receive oxygen as routine supportive therapy following extubation after surgery. Notwithstanding, although it is well established that postoperative pulmonary complications remain a leading cause of postoperative morbidity and mortality after major surgery [1], previous observational studies have noted that critical respiratory events including severe arterial hypoxemia during the early postextubation period are relatively rare events in this specific context [2]. Recent large randomized controlled trials have shown that postoperative pulmonary complications are mainly observed within the first week after surgery (with a peak frequency around postoperative day 2), and are heavily influenced by the use of intraoperative lung-protective ventilation strategies (Fig. 1) [3, 4].

Oxygen therapy after surgery is used to correct residual impairment in oxygenation after removal of the endotracheal tube (or, in some circumstances, the laryngeal mask) resulting from alveolar hypoventilation caused by respiratory depression and inability to maintain an adequate airway and/or from ventilation-to-perfusion mismatch. After extubation, and with spontaneous breathing at atmospheric pressure, functional residual capacity, which was maintained with the use of positive end-expiratory pressure (PEEP) during invasive ventilation, may rapidly decrease with a concomitant reduction in pulmonary oxygen transfer. As indicated by the alveolar gas equation, because the alveolar partial pressure of oxygen mainly relates to the inspired oxygen fraction under steady-state conditions, hypoxemia that might occur secondary to hypoventilation is usually readily corrected by supplemental oxygen. In contrast, although this may normalize oxygen saturation, oxygen therapy alone may not be sufficient to correct the underlying pathophysiologic disturbance when a loss in lung volume is present, as occurs with atelectasis formation. An increasing body of evidence suggests that early

Fig. 1 Main mechanisms of postoperative hypoxemia following tracheal extubation.

Please note that, as indicated by the alveolar gas equation, the alveolar partial pressure of oxygen (PAO_2) mainly depends on the inspired oxygen concentration. PAO_2 Alveolar partial pressure of oxygen, PB barometric pressure, PH_2O water vapor pressure (at 37 °C, $PH_2O = 47$ mmHg), RQ respiratory quotient (its value is typically 0.8 but can range from 0.7 to 1.0), VA/Q ventilation-to-perfusion ratio



administration of prophylactic non-invasive respiratory support after extubation, ranging from continuous positive airway pressure to non-invasive positive pressure ventilation, can prevent acute respiratory failure and reintubation following major surgery [5, 6]. Nonetheless, the fact remains that non-invasive ventilation is not the silver bullet for all patients and affects healthcare utilization, since its application usually requires admission of patients into structures capable of providing high levels of monitoring.

Recently, the high-flow nasal cannula (HFNC) has attracted significant attention from several clinical research groups and has been proposed as a supportive therapy in critically ill patients with acute respiratory failure [7–9], during bronchoscopy [10], or to prevent severe desaturation during intubation of patients with mild-to-moderate hypoxemia [11]. HFNC, which delivers up to 100 % heated and humidified oxygen at a maximum gas flow of 60 l/min via a nasal cannula, offers several physiological advantages that might encourage its use instead of routine oxygen therapy after tracheal extubation. This includes, but is not limited to, improvements in oxygenation, the generation of a flow-dependent PEEP, and an increase in end-expiratory lung volume (EELV) [12, 13]. A recent study in critically ill patients mechanically ventilated for more than 24 h has shown that HFNC applied after tracheal extubation results in better oxygenation than oxygen therapy using a Venturi mask and, more importantly, also significantly reduces the reintubation rate [14].

So why should one not simply do the same in surgical patients? This might be of particular interest, at least theoretically, in this context in view of the importance of strategies aimed at minimizing the reduction in lung volume [15]. In their recent article in *Intensive Care Medicine*, Corley et al. [16] attempt to do just that. On the

basis of previous data in cardiac surgical patients for whom HNFC was found to improve oxygenation and EELV following extubation in a more pronounced way in those with higher BMI [13], they randomized 155 patients with a $BMI \geq 30$ kg/m² to receive HFNC therapy (gas flow titrated on patient comfort and up to 50 l/min) or standard oxygen therapy (delivered at 2–4 l/min via nasal cannula or 6 l/min via simple facemask) after tracheal extubation (using well-defined criteria) with the objective in the two arms to maintain $SpO_2 \geq 95$ %. The authors hypothesized that HFNC may enhance respiratory status and, consequently, may reduce the degree of atelectasis (the primary endpoint) as assessed by a radiological atelectasis score. In the end, despite moderate improvement in oxygenation in the first 8 h of treatment, they found that HFNC did not confer any statistically, nor clinically relevant, differences in the primary and pre-specified secondary endpoints, including the need for escalation to other respiratory support modalities. At first glance, there appears to be little positive that can be taken from this trial, with most of the results being already brought to our attention by another study in cardiac surgical patients [17]. We should, however, not be too hasty in throwing out the baby with the bathwater, given the multiplicity of causative factors that can contribute to explain some of the discrepancies with data in ICU patients [14]. The most obvious of these lies in the characteristics of patients subjected to oxygen therapy whose impairment in lung function might have been insufficient to expect a significant benefit of any kind whatsoever. Even among those who meet weaning criteria and successfully perform a weaning test, 10–20 % of ICU patients can experience postextubation respiratory failure, which has obviously little connection with the perioperative context. It should be borne in mind that, although attractive, only a few data support direct use of HFNC

after extubation and, because failure of HNFC may delay intubation and increase mortality [18], its use as routine therapy deserves further evaluation.

More relevant to the question at hand, clinicians must be aware that postextubation respiratory support should ideally complement what comes before, since **most postoperative respiratory events are above all influenced by intra-operative determinants** [15]. Unfortunately, the present study does not provide information on patients' individual risk factors for postoperative pulmonary complications and intra-operative ventilator settings. The last point in particular is, from our point of view, an important limitation of the study. Indeed, as efficient as it may be, it is **difficult to conceive a benefit of HFNC therapy in the surgical context outside the framework of a multifaceted approach of lung-protection**. In this particular respect, the data of the multicenter OPERA study recently completed (ClinicalTrials.gov Identifier: NCT01887015) will hopefully provide valuable additional information. In addition, although most patients are suspected to be at low or moderate preoperative risks, it cannot be ruled out that there may be an additional benefit of HFNC in patients

with higher risks of complications. Finally, the authors may have been somewhat ambitious in envisaging a substantial reopening of atelectasis from the application of no more than 3–4 cmH₂O of PEEP with HNFC [12], when PEEP levels up to 10 cmH₂O may be required with the use of NIV.

In summary, the authors have to be praised for the ambition of conducting this study, and the conclusion we should draw is that the use of HNFC should not be recommended after extubation of obese cardiac surgical patients. This, however, cannot be considered definitive and some important questions remain unanswered before concluding that we need to remove our old-fashioned nasal cannulas from our arsenal or, in contrast, that they are still up to it.

Conflicts of interest Dr. Futier reports receiving consulting fees from General Electrics Medical System and Dräger, and travel reimbursement for meeting from Fisher and Paykel Dr. Jaber reports receiving consulting fees from Dräger, Maquet, Hamilton and Fisher & Paykel.

References

1. Serpa Neto A, Hemmes SN, Barbas CS, Beiderlinden M, Fernandez-Bustamante A, Futier E, Hollmann MW, Jaber S, Kozian A, Licker M, Lin WQ, Moine P, Scavonetto F, Schilling T, Selmo G, Severgnini P, Sprung J, Treschan T, Unzueta C, Weingarten TN, Wolthuis EK, Wrigge H, Gama de Abreu M, Pelosi P, Schultz MJ (2014) Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic review and meta-analysis. *Lancet Respir Med* 2:1007–1015
2. Rose DK, Cohen MM, Wigglesworth DF, DeBoer DP (1994) Critical respiratory events in the postanesthesia care unit. Patient, surgical, and anesthetic factors. *Anesthesiology* 81:410–418
3. Futier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A, Marret E, Beaussier M, Gutton C, Lefrant JY, Allaouchiche B, Verzilli D, Leone M, De Jong A, Bazin JE, Pereira B, Jaber S (2013) A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med* 369:428–437
4. Hemmes SN, Gama de Abreu M, Pelosi P, Schultz MJ (2014) High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial. *Lancet* 384:495–503
5. Cabrini L, Landoni G, Oriani A, Plumari VP, Nobile L, Greco M, Pasin L, Beretta L, Zangrillo A (2015) Noninvasive ventilation and survival in acute care settings: a comprehensive systematic review and metaanalysis of randomized controlled trials. *Crit Care Med* 43:880–888
6. Ireland CJ, Chapman TM, Mathew SF, Herbison GP, Zacharias M (2014) Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery. *Cochrane Database Syst Rev* 8:CD008930
7. Sztymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, Ricard JD (2011) Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. *Intensive Care Med* 37:1780–1786
8. Cuquemelle E, Pham T, Papon JF, Louis B, Danin PE, Brochard L (2012) Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. *Respir Care* 57:1571–1577
9. Messika J, Ben Ahmed K, Gaudry S, Miguel-Montanes R, Rafat C, Sztymf B, Dreyfuss D, Ricard JD (2015) Use of high-flow nasal cannula oxygen therapy in subjects with ARDS: a 1-year observational study. *Respir Care* 60:162–169
10. Simon M, Braune S, Frings D, Wiontzek AK, Klose H, Kluge S (2014) High flow nasal cannula oxygen versus non-invasive ventilation in patients with acute hypoxaemic respiratory failure undergoing flexible bronchoscopy—a prospective randomised trial. *Crit Care* 18:712
11. Miguel-Montanes R, Hajage D, Messika J, Bertrand F, Gaudry S, Rafat C, Labbe V, Dufour N, Jean-Baptiste S, Bedet A, Dreyfuss D, Ricard JD (2015) Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. *Crit Care Med* 43:574–583
12. Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, Galia F, Futier E, Constantin JM, Jaber S (2013) Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. *Minerva Anestesiol* 79:1344–1355

-
13. Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF (2011) Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in postcardiac surgical patients. *Br J Anaesth* 107:998–1004
 14. Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M (2014) Nasal high-flow versus venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med* 190:282–288
 15. Futier E, Marret E, Jaber S (2014) Perioperative positive pressure ventilation: an integrated approach to improve pulmonary care. *Anesthesiology* 121:400–408
 16. Corley A, Bull T, Spooner AJ, Barnett AG, Fraser JF (2015) Direct extubation onto high-flow nasal cannulae postcardiac surgery versus standard treatment in patients with a BMI ≥ 30 : a randomised controlled trial. *Intensive Care Med* 41:887–894
 17. Parke R, McGuinness S, Dixon R, Jull A (2013) Open-label, phase II study of routine high-flow nasal oxygen therapy in cardiac surgical patients. *Br J Anaesth* 111:925–931
 18. Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M, Seo HS, Suh HJ, Seo GJ, Kim EY, Hong SB (2015) Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. *Intensive Care Med* 41:623–632